Drugs / hLF1-11
hLF1-11
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00430469 | Nov 2008 → Mar 2009 | bacterial infectious disease, fungal infectious disease | AM-Pharma | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00509834 | Jul 2008 → Jan 2009 | candidemia | AM-Pharma | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00509938 | Mar → Nov 2006 | disease related to hematopoietic stem cell transplant, infectious disease | AM-Pharma | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hLF1-11 | “Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11).” PMID 19735580 ↗ Sep 2009 |
| Known as | human lactoferrin 1-11 | “human lactoferrin 1-11” NCT00509834 ↗ |
| Known as | human lactoferrin peptide 1-11 | “Drug: human lactoferrin peptide 1-11” NCT00509938 ↗ |
| Known as | human lactoferrrin 1-11 | “promising new antimicrobial peptide human lactoferrrin 1-11 (hLF1-11) in healthy volunteers and patients.” PMID 19735580 ↗ Sep 2009 |
| Modality | Peptide | “The peptide representing the first cationic domain, i.e. the peptide comprising the first eleven residues of hLF (further referred to as hLF1-11)” NCT00430469 ↗ |
| Route | Intravenous | “IV administration” NCT00509834 ↗ |